GO analysis and GSEA revealed disruption of MAPK, E2F and MYC pathways, echoing two very recent studies also reporting KIF26A’s involvement in MYC and E2F pathways in cancer (Ma et al., 2021; Xu et al., 2020). The gene discussed is KIF26A; the disease is cancer.